

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

ETAS ID: TM717776

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>SEQUENCE:</b>	1

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
BAUSCH + LOMB IRELAND LIMITED		03/28/2022	Private Limited Company: IRELAND
BAUSCH & LOMB INCORPORATED		03/28/2022	Corporation: NEW YORK
ORAPHARMA, INC.		03/28/2022	Corporation: DELAWARE
SOLTA MEDICAL, INC.		03/28/2022	Corporation: DELAWARE
TECHNOLAS PERFECT VISION GMBH		03/28/2022	Gesellschaft Mit Beschränkter Haftung (GmbH): GERMANY

## RECEIVING PARTY DATA

<b>Name:</b>	Barclays Bank PLC, as Collateral Agent
<b>Street Address:</b>	745 Seventh Avenue
<b>City:</b>	New York
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10019
<b>Entity Type:</b>	PLC: ENGLAND

## PROPERTY NUMBERS Total: 16

Property Type	Number	Word Mark
Serial Number:	97224482	EYELUMA
Serial Number:	97224477	ILUMA
Serial Number:	97224502	IXPLOR
Serial Number:	97225373	OPTISOL
Serial Number:	97224493	SEELUMA
Serial Number:	97224475	SEENOVA
Serial Number:	97217507	ORAPORTAL
Serial Number:	97212859	
Serial Number:	97155455	ACE ADVANCED CORNEAL EXPLORER
Serial Number:	97093902	BAUSCH + LOMB REVIVE
Serial Number:	97093019	IMAYZI
Serial Number:	97093033	JEVRIQ

OP \$415.00 97224482

Property Type	Number	Word Mark
Serial Number:	97093009	LUCAMZI
Serial Number:	97093042	OPHELZI
Serial Number:	97093057	RALZYRIS
Serial Number:	97063941	REVIVE

# **CORRESPONDENCE DATA**

**Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 800-494-5225

**Email:** ipteam@cogencyglobal.com

**Correspondent Name:** Stewart Walsh

**Address Line 1:** 1025 Connecticut Ave NW, Suite 712

**Address Line 2:** COGENCY GLOBAL Inc.

**Address Line 4:** Washington, D.C. 20036

<b>NAME OF SUBMITTER:</b>	Ashley Min Joo Kim
---------------------------	--------------------

<b>SIGNATURE:</b>	/Ashley Min Joo Kim/
-------------------	----------------------

<b>DATE SIGNED:</b>	03/30/2022
---------------------	------------

## **Total Attachments: 8**

source=Trademark IPSA - Q4 2021 (Barclays) (with coversheet)#page3.tif

source=Trademark IPSA - Q4 2021 (Barclays) (with coversheet)#page4.tif

source=Trademark IPSA - Q4 2021 (Barclays) (with coversheet)#page5.tif

source=Trademark IPSA - Q4 2021 (Barclays) (with coversheet)#page6.tif

source=Trademark IPSA - Q4 2021 (Barclays) (with coversheet)#page7.tif

source=Trademark IPSA - Q4 2021 (Barclays) (with coversheet)#page8.tif

source=Trademark IPSA - Q4 2021 (Barclays) (with coversheet)#page9.tif

source=Trademark IPSA - Q4 2021 (Barclays) (with coversheet)#page10.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of March 28, 2022, (this “**Agreement**”), among the entities identified as grantors on the signature pages hereto (collectively, the “**Grantors**”) and Barclays Bank PLC (“**Barclays**”), as collateral agent (in such capacity, the “**Collateral Agent**”) for the Secured Parties.

Reference is made to that certain Third Amended and Restated Pledge and Security Agreement, dated as of June 1, 2018 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time and in effect on the date hereof, the “**Security Agreement**”), among the Loan Parties party thereto and the Collateral Agent. The Lenders (as defined below) have extended credit to the Borrowers subject to the terms and conditions set forth in that certain Fourth Amended and Restated Credit and Guaranty Agreement dated as of June 1, 2018 (as amended, restated, amended and restated, supplemented or otherwise modified and in effect on the date hereof, the “**Credit Agreement**”), by and among Bausch Health Companies, Inc. (formerly known as Valeant Pharmaceuticals International, Inc., the “**Parent**”), Bausch Health Americas, Inc. (formerly known as Valeant Pharmaceuticals International, and, together with the Parent, the “**Borrowers**”), certain subsidiaries of the Parent, as subsidiary guarantors, the Lenders from time to time party thereto (the “**Lenders**”), and Barclays, in its capacities as the Swingline Lender and as Administrative Agent for the Lenders. Consistent with the requirements set forth in Sections 4.01 and 5.12 of the Credit Agreement and Section 4.3 of the Security Agreement, the parties hereto agree as follows:

SECTION 1. *Terms.* Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Security Agreement.

SECTION 2. *Grant of Security Interest.* As security for the prompt and complete payment or performance, as the case may be, in full of the Secured Obligations, each Grantor, pursuant to the Security Agreement, did and hereby does pledge, collaterally assign, mortgage, transfer and grant to the Collateral Agent, its successors and permitted assigns, on behalf of and for the ratable benefit of the Secured Parties, a continuing security interest in all of its right, title or interest in, to or under all of the following assets, whether now owned or at any time hereafter acquired by or arising in favor of such Grantor and regardless of where located (the Trademark Collateral, Patent Collateral and Copyright Collateral, each as defined below, collectively, the “**IP Collateral**”):

A. The “**Trademark Collateral**”, defined as set forth in paragraphs (1) through (4) directly below:

1. all Trademarks, including those Trademark registrations and registration applications in the United States Patent and Trademark Office listed on Schedule I hereto;
2. all goodwill associated with or symbolized by the Trademarks;
3. the right to sue third parties for past, present and future infringements, dilutions or violations of any Trademark; and
4. all proceeds of and rights associated with the foregoing;

B. The “**Patent Collateral**”, defined as set forth in paragraphs (1) through (3) directly below:

1. all Patents, including those Patent registrations and pending applications in the United States Patent and Trademark Office listed on Schedule II hereto;

2. the right to sue third parties for past, present and future infringements of any Patent; and
3. all proceeds of and any right associated with the foregoing; and

C. The “**Copyright Collateral**”, defined as set forth in paragraphs (1) through (3) directly below:

1. all Copyrights, including those Copyright registrations and pending applications for registration in the United States Copyright Office listed on Schedule III;
2. the right to sue third parties for past, present and future infringements of any Copyright, and
3. all proceeds of and rights associated with the foregoing;

Notwithstanding anything to the contrary in (A) through (C) above, this Agreement shall not constitute a grant of a security interest in any Excluded Assets, including any “intent-to-use” Trademark applications prior to the filing and acceptance of a “Statement of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto.


**SECTION 3. *Security Agreement.*** The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the IP Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.

**SECTION 4. *Governing Law.*** This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.


**SECTION 5. *Counterparts.*** This Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart to this Agreement by facsimile transmission or other electronic transmission (such as .pdf or .tif) shall be effective as delivery of a manually signed counterpart of this Agreement.

[Remainder of page intentionally left blank]


BAUSCH HEALTH IRELAND LIMITED

By:   
\_\_\_\_\_  
Name: William N. Woodfield  
Title: Director


BAUSCH+LOMB IRELAND LIMITED

By:   
\_\_\_\_\_  
Name: William N. Woodfield  
Title: Director


SALIX PHARMACEUTICALS, INC.

By:   
\_\_\_\_\_  
Name: William N. Woodfield  
Title: Vice President, Treasurer


BAUSCH & LOMB INCORPORATED

By:   
\_\_\_\_\_  
Name: William N. Woodfield  
Title: Vice President, Treasurer


BAUSCH HEALTH US, LLC

By:   
\_\_\_\_\_  
Name: William N. Woodfield  
Title: Senior Vice President and Treasurer


SOLTA MEDICAL, INC.

By:   
\_\_\_\_\_  
Name: William N. Woodfield  
Title: Director

TECHNOLAS PERFECT VISION GMBH

By:   
\_\_\_\_\_  
Name: William N. Woodfield  
Title: Managing Director

ORAPHARMA, INC.

By:   
\_\_\_\_\_  
Name: William N. Woodfield  
Title: Vice President, Treasurer

Accepted and Agreed:

**BARCLAYS BANK PLC,**  
as Collateral Agent

By:

DocuSigned by:  
*Robert Walsh*  
.....FCDAF84F50AA411....

---

Name: Robert Walsh  
Title: Assistant Vice President

**Schedule I - Trademark Collateral** **Schedule I - Trademark Collateral**

Current Owner on TMO Records	Mark Name	Current Application Number	Current Registration Number
BAUSCH + LOMB IRELAND LIMITED	EYELUMA	97224482	N/A
BAUSCH + LOMB IRELAND LIMITED	ILUMA	97224477	N/A
BAUSCH + LOMB IRELAND LIMITED	IXPLOR	97224502	N/A
BAUSCH & LOMB INCORPORATED	OPTISOL	97225373	N/A
BAUSCH + LOMB IRELAND LIMITED	SEELUMA	97224493	N/A
BAUSCH + LOMB IRELAND LIMITED	SEENOVA	97224475	N/A
ORAPHARMA, INC.	ORAPORTAL	97217507	N/A
SOLTA MEDICAL, INC.	CIRCLE DOT DESIGN LOGO (Clear + Brilliant brand)	97212859	N/A
TECHNOLAS PERFECT VISION GMBH	ACE ADVANCED CORNEAL EXPLORER (LOGO)	97155455	N/A
BAUSCH + LOMB IRELAND LIMITED	BAUSCH + LOMB REVIVE	97093902	N/A
BAUSCH + LOMB IRELAND LIMITED	IMAYZI	97093019	N/A
BAUSCH + LOMB IRELAND LIMITED	JEVRIQ	97093033	N/A
BAUSCH + LOMB IRELAND LIMITED	LUCAMZI	97093009	N/A
BAUSCH + LOMB IRELAND LIMITED	OPHELZI	97093042	N/A
BAUSCH + LOMB IRELAND LIMITED	RALZYRIS	97093057	N/A
BAUSCH + LOMB IRELAND LIMITED	REVIVE	97063941	N/A



**Schedule II – Patent Collateral**

<b>Appl. No.</b>	<b>Publ. No.</b>	<b>Patent No.</b>	<b>Title</b>	<b>Current PTO Owner</b>
17/694981			BIOMEDICAL DEVICES	BAUSCH + LOMB IRELAND LIMITED
17/691260			CONTACT LENS TREATING SOLUTION	BAUSCH + LOMB IRELAND LIMITED
17/691263			PRESERVATIVE-FREE CONTACT LENS TREATING SOLUTION	BAUSCH + LOMB IRELAND LIMITED
17/561198			COMPOSITIONS AND METHODS FOR TREATING DISEASES OF THE NAIL	BAUSCH HEALTH IRELAND LIMITED
17/550220			PACKAGING SOLUTIONS	BAUSCH & LOMB INCORPORATED
17/533454	2022-0081491-A1		CROSSLINKED POLYMERIC NETWORK AND USE THEREOF	BAUSCH & LOMB INCORPORATED
17/533978			METHOD FOR MAKING A PRESERVATIVE-FREE PACKAGED OPHTHALMIC DEVICE PRODUCT	BAUSCH + LOMB IRELAND LIMITED
17/299578	2022-0022937-A1		CERAMIC APPLICATOR FOR TRANSCUTANEOUS DELIVERY OF ENERGY	BAUSCH HEALTH IRELAND LIMITED
17/299611	2022-0015818-A1		MICROBLADE STRUCTURE AND METHOD OF TREATING TISSUE	BAUSCH HEALTH IRELAND LIMITED
17/468457	2021-0401813-A1		SOLID DISPERSION FORMS OF RIFAXIMIN	SALIX PHARMACEUTICALS, INC.
17/478027	2021-0403508-A1		ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME	BAUSCH HEALTH IRELAND LIMITED
17/468461	2022-0040157-A1		SOLID DISPERSION FORMS OF RIFAXIMIN	SALIX PHARMACEUTICALS, INC.

None.

Schedule III - Copyright Collateral